Michel Baijot

Directeur/Membre du Conseil chez EXPRES2ION BIOTECH HOLDING AB

Profil

Michel Baijot is currently Chairman at OncoRadiomics SA since 2018, Chairman at Curavac, Inc., Director at Antelope Dx BV, Director at Antelope Diagnostics since 2020, Director at Expres2ion Biotech Holding AB starting 2026, and President at White Fund SA since 2019.
Former roles include Chief Executive Officer, MD & Director at European Medical Solutions from 2018 to 2020, Executive Director-Europe Region at Serum Institute of India Pvt Ltd. from 2016 to 2017, Director at Ire EliT NV from 2015 to 2018, Vice President-Business Development at Fujirebio Europe NV from 2000 to 2005, Vice President-Business Development at GlaxoSmithKline Biologicals SA from 2005 to 2011, and Chief Business Officer & Head-Cipla Global Vaccine at Janssen, Inc. from 2011 to 2014.
Education includes a doctorate from Université Catholique de Louvain.

Postes actifs de Michel Baijot

Sociétés	Poste	Début
EXPRES2ION BIOTECH HOLDING AB	Directeur/Membre du Conseil	01/04/2026
OncoRadiomics SA	Président	01/01/2018
White Fund SA	President	01/01/2019
Antelope Diagnostics	Directeur/Membre du Conseil	01/09/2020
Antelope Dx BV	Directeur/Membre du Conseil	-
Curavac, Inc.	Président	-
White Fund	Président	-

Anciens postes connus de Michel Baijot

Sociétés	Poste	Fin
IRE ELiT SRL	Directeur/Membre du Conseil	01/01/2018
Serum Institute of India Pvt Ltd.	Corporate Officer/Principal	01/01/2017
░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░░░░░░░░ ░░░░░░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░
░░░░░░░░░ ░░░░░░ ░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░